Ozanimod Superior to Avonex in Treating Relapsing MS in Phase 3 Trials, Celgene Reports

Source Multiple Sclerosis News Today:  

Celgene released the results of two Phase 3 trials showing that patients with relapsing multiple sclerosis (MS) who were treated with ozanimod had lower relapse rates and fewer MRI brain lesions compared to those given a current first-line therapy, Avonex (interferon β-1a).

These results will be used to support a request for ozanimod’s approval as an MS therapy  with the U.S. Food and Drug Administration (FDA), a filing known as a  New Drug Application.  Read on.

Leave a Reply

  • (will not be published)